Pharmaceuticals
-
Eli Lilly Widens Obesity Drug Lead with Zepbound Wins
Eli Lilly solidified its dominance in the obesity drug market on Monday. New trial data showed Zepbound’s superior efficacy, and a multi-dose KwikPen launched.
-
Wegovy Pill Copy: Hims & Hers Shakes Weight-Loss Drug Market
Telehealth company Hims & Hers announced it will offer a $49 copy of Novo Nordisk’s popular Wegovy pill, causing significant shifts in the stock market for major pharmaceutical firms.
-
Novo Nordisk CEO Unveils Aggressive Strategy to Reclaim GLP-1 Market Lead, Targets 2 Billion People
Novo Nordisk’s new CEO Maziar Mike Doustdar outlines a bold three-pronged strategy for 2026, aiming to reclaim market dominance in the GLP-1 obesity drug sector from rival Eli Lilly. The plan focuses on commercial execution, pipeline progression, and a return…
-
Sarah Jessica Parker Joins Lenz Therapeutics to Make Age-Related Blurry Vision ‘VIZZable’
Lenz Therapeutics has launched its ‘Make it VIZZable’ consumer campaign, featuring acclaimed actor Sarah Jessica Parker as a brand ambassador for VIZZ. The campaign aims to highlight solutions for age-related blurry near vision, with Parker sharing her personal experiences and…
-
Wegovy Pills Set to Transform Weight Loss Market Amid Cost and Accessibility Concerns
Novo Nordisk’s new Wegovy pill is set to launch in the US, promising more accessible weight loss treatments for those who avoid injections. Yet, high prices and insurance barriers remain major obstacles for millions seeking medical help for obesity.
-
Pfizer Stock Outlook for 2026: Dividend Strength, Pipeline Rebuild, and Analyst Forecasts
Pfizer stock (PFE) enters 2026 with steady dividends, a cautious analyst consensus, and renewed pipeline investments. Investors weigh the impact of new obesity drug deals, immunology partnerships, and the looming patent cliff, as the company prepares to release critical full-year…
-
Eli Lilly Stock Surges After Record Q3 Earnings and Raised Guidance
Eli Lilly delivered a standout third quarter, beating Wall Street forecasts on both earnings and revenue, fueled by soaring demand for diabetes and obesity treatments. The company raised its full-year guidance, signaling strong growth momentum and investor confidence.
-
AstraZeneca and Trump’s Drug Pricing Deal
AstraZeneca and the Trump administration struck a landmark deal to reduce U.S. drug prices using a ‘most-favored-nation’ pricing model, with major implications for healthcare affordability and pharmaceutical policy.
-
Singapore’s Pharma Sector Eyes US Tariff Exemptions After Trump’s New Duties
Singapore’s pharmaceutical industry may dodge immediate fallout from sweeping new US tariffs, as firms with American operations seek clarity and possible exemptions under President Trump’s latest trade moves.
-
US Investigates Tariffs on Computer Chips and Pharmaceuticals
The US has launched investigations into computer chip and pharmaceutical imports, aiming to assess their impact on national security and domestic production.
-
Mustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio has announced the pricing of an $8 million public offering, comprising 2,657,807 shares of common stock (or equivalents) and two series of warrants. The combined offering price is set at $3.01 per share with accompanying warrants. The Series…
-
Medicare Drug Price Negotiations to Continue, with Focus on Transparency
The Centers for Medicare & Medicaid Services (CMS) has announced it will proceed with Medicare drug price negotiations under the current administration, emphasizing a commitment to greater transparency in the process. This second round of negotiations will include high-profile, expensive…